DK0960886T3 - Peptid T og beslægtede peptider til behandling af inflammation, herunder multipel sklerose - Google Patents

Peptid T og beslægtede peptider til behandling af inflammation, herunder multipel sklerose

Info

Publication number
DK0960886T3
DK0960886T3 DK99101349T DK99101349T DK0960886T3 DK 0960886 T3 DK0960886 T3 DK 0960886T3 DK 99101349 T DK99101349 T DK 99101349T DK 99101349 T DK99101349 T DK 99101349T DK 0960886 T3 DK0960886 T3 DK 0960886T3
Authority
DK
Denmark
Prior art keywords
absent
thr
ser
gly
cys
Prior art date
Application number
DK99101349T
Other languages
English (en)
Inventor
David James Phipps
Anders Jorgen Andersen
Peter Louis Carlen
Penelope Reed Doob
Douglas Kevin Macfadden
Deborah Rathjen
Fred Widmer
Roger Aston
Original Assignee
Advanced Immuni T Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK92645A external-priority patent/DK64592D0/da
Application filed by Advanced Immuni T Inc filed Critical Advanced Immuni T Inc
Application granted granted Critical
Publication of DK0960886T3 publication Critical patent/DK0960886T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99101349T 1992-03-27 1993-03-29 Peptid T og beslægtede peptider til behandling af inflammation, herunder multipel sklerose DK0960886T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85883292A 1992-03-27 1992-03-27
DK92645A DK64592D0 (da) 1992-05-14 1992-05-14 Peptider til terapeutisk behandling
US91511892A 1992-07-17 1992-07-17
US98767492A 1992-12-09 1992-12-09
EP99101349A EP0960886B1 (en) 1992-03-27 1993-03-29 Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
EP93907942A EP0635027B1 (en) 1992-03-27 1993-03-29 Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis

Publications (1)

Publication Number Publication Date
DK0960886T3 true DK0960886T3 (da) 2004-09-27

Family

ID=27439352

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93907942T DK0635027T3 (da) 1992-03-27 1993-03-29 Peptid T og beslægtede peptider til behandling af inflammation, herunder dissemineret sclerose
DK99101349T DK0960886T3 (da) 1992-03-27 1993-03-29 Peptid T og beslægtede peptider til behandling af inflammation, herunder multipel sklerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK93907942T DK0635027T3 (da) 1992-03-27 1993-03-29 Peptid T og beslægtede peptider til behandling af inflammation, herunder dissemineret sclerose

Country Status (12)

Country Link
EP (2) EP0960886B1 (da)
JP (1) JP3520084B2 (da)
KR (1) KR100312300B1 (da)
AT (2) ATE194495T1 (da)
AU (3) AU684713B2 (da)
CA (1) CA2132516A1 (da)
DE (2) DE69329023T2 (da)
DK (2) DK0635027T3 (da)
ES (2) ES2222625T3 (da)
PT (1) PT960886E (da)
UA (1) UA41881C2 (da)
WO (1) WO1993020102A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
AU697847B2 (en) * 1993-09-24 1998-10-15 Advanced Immunit, Inc. Method for the treatment or prevention of eczema/dermatitis
DE69433817T2 (de) * 1993-09-24 2005-07-14 Advanced Immuni T, Inc. Lineare und cyklische peptide zur behandlung oder vorbeugung der crohn'schen krankheit und/oder der ulzerativen kolitis
EP1242109A4 (en) * 1999-11-09 2004-06-02 Advanced Immunit Inc METHOD FOR THE TREATMENT OF VIURUS DISEASES AND OTHER DISORDERS BY CHANGING THE IMMEDIATE GENE EXPRESSION BY ADMINISTERING PEPTIDE T
JP4611233B2 (ja) * 2005-04-06 2011-01-12 ニッタ株式会社 歩行訓練支援装置
US20140322251A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions
EP2832373B1 (en) * 2013-08-02 2017-04-12 Experimentelle Pharmakologie & Onkologie Berlin Buch Liposome for blocking site-specifically chemokine-related inflammatory processes in vascular diseases and metastasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7544987A (en) * 1986-06-03 1988-01-11 Pert, C.B. Small peptides which inhibit binding to t-4 receptors
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
WO1988009338A1 (en) * 1987-05-22 1988-12-01 Syntbiotech, Inc. Synthetic peptides and a method of treating aids
ATE168698T1 (de) * 1988-05-27 1998-08-15 Us Health Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
US5189022A (en) * 1988-05-27 1993-02-23 The United States Of America As Represented By The Secretary Of Health And Human Services Composition for the treatment of chronic fatigue syndrome

Also Published As

Publication number Publication date
JPH07507061A (ja) 1995-08-03
AU725680B2 (en) 2000-10-19
UA41881C2 (uk) 2001-10-15
EP0635027A1 (en) 1995-01-25
ATE267838T1 (de) 2004-06-15
EP0960886B1 (en) 2004-05-26
EP0635027B1 (en) 2000-07-12
EP0960886A1 (en) 1999-12-01
JP3520084B2 (ja) 2004-04-19
ATE194495T1 (de) 2000-07-15
CA2132516A1 (en) 1993-10-14
PT960886E (pt) 2004-10-29
DK0635027T3 (da) 2000-10-02
KR950700931A (ko) 1995-02-20
AU718442B2 (en) 2000-04-13
ES2149203T3 (es) 2000-11-01
ES2222625T3 (es) 2005-02-01
WO1993020102A1 (en) 1993-10-14
DE69333537T2 (de) 2005-06-16
AU684713B2 (en) 1998-01-08
AU3895393A (en) 1993-11-08
AU2254999A (en) 1999-05-20
AU6354298A (en) 1998-06-18
DE69329023D1 (de) 2000-08-17
KR100312300B1 (ko) 2002-03-20
DE69329023T2 (de) 2001-03-22
DE69333537D1 (de) 2004-07-01

Similar Documents

Publication Publication Date Title
SE9100799L (sv) Rekombinant derivat av human faktor viii
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
ATE171712T1 (de) Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten
ATE238345T1 (de) Protegrine
DK0711305T3 (da) Protegriner
DK31991D0 (da) Peptid og farmaceutisk praeparat indeholdende et saadant peptid
DK0635027T3 (da) Peptid T og beslægtede peptider til behandling af inflammation, herunder dissemineret sclerose
BR9306272A (pt) Peptídeo e composiçao farmacêutica
RU94027578A (ru) Фармацевтическая композиция и способ лечения рассеянного склероза
CA2006087A1 (en) Polypeptides isolated from the venom of the spider hololena curta
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
ATE221084T1 (de) Neuer megakaryocyten-verstärker
ATE3773T1 (de) An peptide polymerisationsprodukte gebundene muramyl-peptide und sie enthaltende pharmazeutische zusammensetzungen.
CA2102606A1 (en) Compositions for the treatment of chronic fatigue syndrome
RU94046096A (ru) Линейные или циклические пептиды, их применение, способы лечения и конъюгаты пептидов
IL102615A (en) Immunoassy kit for simultaneously detecting antibodies to hiv-1, hiv-2, htlv-1 and htlv-ii and methods for te detections of antibodies
ATE124955T1 (de) Substrat-peptide.
ATE425988T1 (de) Peptide mit affinitat fur ein phospholipid und deren verwendung
ES2051152B1 (es) Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.
RU94036002A (ru) Ингибитор протеазы, днк, вектор, клетка, способ получения ингибитора, фармацевтическая композиция